Masimo Corporation · NASDAQ:MASI
Masimo — Investor Day (May 2019)
7 slides from Masimo's investor day presentation, May 16, 2019
Slide 1: Potential to Expand Our Long-Term Market Opportunity
Potential to Expand Our Long-Term Market Opportunity Total Addressable Market Opportunity Innovation Pipeline Opportunities Pipeline Opportunity $1.0B $5B+ Pipeline Opportunity $0.5B Pipeline Opportunity $0.2B Pipeline Opportunity $1.0B Pipeline Opportunity $1.0B+ $4B+ $15B+ Pipeline Opportunity $1.
Slide 2: Potential to Expand Our Long-Term Market Opportunity
Potential to Expand Our Long-Term Market Opportunity Total Addressable Market Opportunity Innovation Pipeline Opportunities Innovation Pipeline Opportunities Pipeline Opportunity $1.0B Pipeline Opportunity $1.0B $5B Pipeline Opportunity $0.5B Pipeline Opportunity $0.5B Pipeline Opportunity $0.2B Pip
Slide 3: Potential to Expand Our Long-Term Market Opportunity
Potential to Expand Our Long-Term Market Opportunity Total Addressable Market Opportunity Innovation Pipeline Opportunities Innovation Pipeline Opportunities Continuous Non-Invasive PaO2 $1.0B Pipeline Opportunity $1.0B $5B+ Malaria $0.5B Pipeline Opportunity $0.5B Pipeline Opportunity $0.2B Pipelin
Slide 4: PaO2 (mmHg)
PaO2 § PaO2 is a more sensitive SpO2 measurement of changes in blood Invasive PaO2 oxygenation than SaO2 and SpO2 ORi § PaO2 measurements are most Noninvasive PaO2 commonly part of Arterial Blood Gas PaO2 (mmHg) (ABG) testing ($1B market estimate) § Continuous, noninvasive PaO2 would be valuable to
Slide 5: Malaria Screening in Real Time
Malaria Screening in Real Time Signals from Skin Without Malaria § 435,000 Malaria-related deaths in 2017 0.01 (WHO)1 0.00 -0.01 Signal amplitude, V -0.02 § Symptoms can be vague or absent for up to -0.03 30 days -0.04 -0.05 -0.06 § Masimo has shown feasibility for point-of-care -0.07 invasive and n
Slide 6: Key Takeaways
Key Takeaways § No one innovates like Masimo! § Our relentless focus on patient safety has not only benefited patients, clinicians, and hospitals, but also Masimo shareholders § Dedicated and talented team has consistently delivered on our commitments § Long-term revenue growth of 8 – 10% with upsid
Slide 7: Investor Day
Investor Day Improving Patient Outcomes May 16, 2019 Reducing the Cost of Care®